New rules for drug labeling in Brazil

On July 3, Collegiate Board Resolution (RDC) 768/2022, which deals with the new rules for drug labeling in Brazil, entered into force. With this, Anvisa also updated the subject codes for petitions on the subject.

Aiming at regulatory simplification, there will be a reduction from 26 to four codes. The new codes address only the type of petition (amendment, notification, inclusion of new destination and adaptation to RDC 768/2022), without specifying the regulatory category of the medicine.

Thus, from now on, companies must use new subject codes. Learn more here

ELS can and is able to consult and assist with labeling issues for medicines and other products in Europe and LATAM to comply with current legislation.

Please contact your ELS local consultant or through the email: info@elssolutions.pt

ELS Group

ELS Group brings together a team of highly specialized professionals with proven experience in regulatory frameworks and compliance in the pharmaceutical field.

Strategic consulting for the pharmaceutical, healthcare, food, and medtech industries.

Rely on experts to support your regulatory decisions and accelerate the growth of your products safely and efficiently.

Strategic consulting for the pharmaceutical, healthcare, food, and medtech industries.

Experts in pharmaceutical consulting, regulatory strategy, and market access to support your company with safety, compliance, and efficiency. Talk to a consultant.